

PRELIMINARY PROGRAMME

26 May 2017

ITALIAN LANGUAGE SYMPOSIUM PHARMACOLOGY IN INTERVENTIONAL CARDIOLOGY

DAPT AFTER PCI

10.00 **CONTROVERSY 1 - P2Y12 INHIBITION AFTER PCI IN STABLE PATIENTS**

Clopidogrel remains the best option in real life
Direct-acting P2Y12 inhibitors should be preferred
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

10.45 **CONTROVERSY – WHICH P2Y12 INHIBITOR SHOULD WE USE IN ACS?**

What guidelines suggest
What real world registries show
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

LONG-TERM MANAGEMENT OF PCI PATIENTS

11.30 **CONTROVERSY 1 – THERAPY IN HIGH RISK PATIENTS**

Medical therapy optimization with multiple drugs
The newer 'Polypill' is the solution
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

12.15 **CONTROVERSY 2 – ADHERENCE TO DRUGS**

Compliance to treatment as a major determinant of outcome
Strategies to improve patient adherence to treatment
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

12.30 **LUNCH**

ANTICOAGULATION IN PCI PATIENTS WITH ATRIAL FIBRILLATION

14.00 **CONTROVERSY 1 – THE CHOICE OF NOACS AFTER PCI**

Phase 3 trials only must guide drug selection
Real world data help physicians' choice
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

14.45 **CONTROVERSY 2 – NOACS IN PCI AND SURGERY**

Should NOACs be interrupted in case of PCI?
How NOACs should be used in case of surgery?
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

THE FUTURE OF ANTIPLATELETS AND ANTICOAGULANTS AFTER PCI

15.30 **CONTROVERSY 1 – THE FUTURE OF P2Y12 INHIBITION**

Life long dual antiplatelet therapy
Only ticagrelor without aspirin
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

16.15 **CONTROVERSY 2 – THE FUTURE OF NOACS**

Will NOACs and aspirin never be associated?
Will NOACs become indicated also in patients with SCA?
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

PARALLEL WORKSHOP ABOUT CLINICAL TRIALS

26 MAY 2017

08.45 Welcome introduction and course objectives
Giuseppe Rosano (UK), Sven Wassmann (Germany)

08.55 Perspectives of an Editor-In-Chief
Stefan Agewall (Norway)

SESSION 1. HOW TO DESIGN AND RUN A CLINICAL TRIAL

09.10 An overview of the different aspects of clinical trials
A. Niessner

- 09.50 Traditional versus novel trial designing
Giuseppe Rosano (UK)
- 10.20 Planning and organising a clinical trial
Basil Lewis (Israel)
- 10.40 The logistics of running a clinical trial
Basil Lewis (Israel)
- 11.00 Refreshments and networking
- SESSION 2. REGULATORY ASPECTS**
- 11.30 Requirements from regulatory agencies: endpoints, comparators, type of studies
Giuseppe Rosano (UK)
- 12.00 Post marketing surveillance
T. Walther
- 12.30 Lunch and networking
- SESSION 3. TRIAL CATEGORIES**
- 13.30 Observational trials and registries
G. L. Savarese (Italy)
- 13.50 Randomised controlled trials
A. Niessner
- 14.10 Meta-analyses and systematic reviews
G. L. Savarese (Italy)
- SESSION 4. WHAT'S NEXT – UPCOMING AND ONGOING CLINICAL TRIALS**
- 14.30 ACS / Antithrombotics
Basil Lewis (Israel) / S. Wassmann (Germany)
- 14.45 Lipidology
H. Drexel (Austria)
- 15.00 Diabetes
H. Drexel (Austria)
- 15.15 Heart Failure
M. Lainscak (Slovenia)
- 15.30 Refreshments and networking

SESSION 5: GOOD CLINICAL PRACTICE

16.00 GCP for the busy investigator (certificate included)
D. Rolfe

18.00 Close of day 1

27 MAY 2017

08.00 Welcome and objectives
Giuseppe Rosano (UK), Sven Wassmann (Germany)

08.05 STATISTICAL ISSUES IN CLINICAL TRIALS – BASIC NOTIONS
Parallel groups (switch after 60 min):

- Randomised controlled trials and subgroup analyses - A. **Niessner**
- Registries and meta-analyses - G.L. **Savarese**

10.00 Refreshments and networking

10.30 **HOW TO INTERPRET CLINICAL TRIAL DATA**
Examples from recent clinical trials
S. Wassmann (Germany) + Panelists

12.00 **THINGS TO KNOW FOR JUNIOR INVESTIGATORS**
Parallel groups:

- How to write a manuscript - S. Wassmann (Germany)
- What you need to know as junior investigator - G. Rosano (UK)

12.30 Closing remarks
G. Rosano (UK), S. Wassmann (Germany)

12.45 Lunch and networking
Close of day 2

26 May 2017

17.00 **EuroCVP 2017 OPENING CEREMONY**

18.00 **END OF DAY 1**

27 May 2017

NEW TARGETS IN THE PREVENTION OF CARDIOVASCULAR DISEASE

Chairs: Basil Lewis (Israel), Stefan Agewall (Norway)

09.00 The pharmacological and non-pharmacological approach to cardiovascular prevention
Massimo Piepoli (Italy)

09.45 The management of lipid profile according to the ESC Guidelines
Heinz Drexel (Austria)

10.30 Management of altered glucose metabolism
Itamar Raz (Israel)

DIABETES MELLITUS: A CARDIOVASCULAR DISEASE

Chairs: Stefan Anker (Germany), Massimo Piepoli (Italy)

11.00 Cardiovascular risk in diabetics
Gianluigi Savarese (Sweden)

11.30 Lenient or intensive control of glycaemia?
Itamar Raz (Israel)

12.00 Effective at last – The new glucose-lowering drugs that reduce cardiovascular events
Thomas Walther (Ireland)

12.30 **LUNCHEON SYMPOSIUM**
PHARMACOLOGY OF ANTI-ISCHAEMIC THERAPY

HOW TO TREAT THE DIFFICULT PATIENT?

Chairs: Claudio Ceconi (Italy), Juan Carlos Kaski (UK)

14.30 Elderly patients with heart failure co-morbidities
Andrew Coats (UK)

15.00 Patients with acute coronary syndromes receiving oral anticoagulants
Torp Pederson (Denmark)

15.30 Ischaemic heart failure with renal and/or liver failure
Claudio Ceconi (Italy)

Joint Session with the HEART FAILURE ASSOCIATION



PHARMACOTHERAPY OF HEART FAILURE

Chairs: Petar Seferovic (Serbia), Thomas Walther (Ireland)

16.00 How to implement the pharmacological therapy of patients with HFrEF
Stefan Anker (Germany)

16.30 Optimisation of RAASi – How can we manage K+
Lars Lund (Sweden)

17.00 The treatment of patients with advanced heart failure
Marco Metra (Italy)

17.30 **END OF DAY 2**

28 May 2017

UPDATE ON ORAL ANTICOAGULATION

Chairs: Juan Tamargo (Spain), Thomas Schmidt (Denmark)

09.00 NOACs for patients with venous thromboembolism and atrial fibrillation
Alexander Niessner (Austria)

09.30 How can we individualise NOACs in everyday practice?
Giuseppe Rosano (UK)

10.00 Anticoagulation in the difficult patient: how to choose the right drug
Sven Wassmann (Germany)

10:30 **OPEN COFFEE BREAK WITH PANEL DISCUSSION**
NOAC antidotes. How relevant for clinical practice?
Panel: Basil Lewis (Israel), Alexander Niessner (Austria),
Giuseppe Rosano (UK), Sven Wassmann (Germany)

Current status of antidotes and reversal agents for NOAC
Juan Tamargo (Spain)

MODERN MANAGEMENT OF CHRONIC ISCHAEMIC HEART DISEASE

Chairs: Maurizio Volterrani (Italy) – Dan Atar (Norway)

11.00 Targets for the modern pharmacologic treatment of chronic ischaemic heart disease
Juan Carlos Kaski (UK)

11.30 Combination therapy for the optimal management of chronic stable angina
Giuseppe Rosano (UK)

12.00 Heart rate and cardiac metabolism optimisation
Maurizio Volterrani (Italy)

12.30 Closing discussion

13.00 **END OF DAY 3**

Organisers

EUROPEAN SOCIETY OF CARDIOLOGY

The European Heart House
Les Templiers
2035 route des colles
CS 80179 BIOT
06903 - Sophia Antipolis Cedex
France



MICOM Srl

Via B. Verro, 12
20141 - Milan
Italy



Supported by:

Società Italiana di Cardiologia (SIC)
Società Italiana Cardiologia Ospedalita' Accreditata (SICOA)

(Requests pending)

Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
Italian Heart Failure Association (ITAHFA)

CME Provider and Secretariat



MICOM Srl
Via B. Verro, 12
20141 - Milan
Italy
Tel. +44 02 89 51 88 95
Fax +44 02 89 51 89 54
E-mail: info@eurocvp.com
Website: www.eurocvp.com

Location:

NH Collection Roma Vittorio Veneto
Corso D'Italia 1
00198 - Rome
Italy